サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566959

動物幹細胞療法市場：タイプ別、種別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Animal Stem Cell Therapy Market By Type (Allogenic, Autologous) , By Species (Dog, Cat, Horse) By End User (Veterinary Hospitals, Research Organizations) : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 260 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
動物幹細胞療法市場：タイプ別、種別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 260 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

動物幹細胞療法市場

動物幹細胞療法市場は、2023年に2億5,600万米ドルと評価され、2024～2033年にかけてCAGR 5.6%で成長し、2033年には4億4,000万米ドルに達すると予測されています。

動物幹細胞療法とは、動物の怪我を治療したり病気を治したりするために幹細胞を使用する治療法です。幹細胞は生体内の未分化細胞であり、異なる機能を持つ新しい細胞を生み出す能力を持っています。幹細胞のこの能力は、損傷した組織や臓器の修復に不可欠です。幹細胞は、骨髄、臍帯血、脂肪組織など、身体の様々な部位から採取されます。この治療法は、変形性関節症、神経疾患、腱や靭帯の損傷、様々な自己免疫疾患など、様々な症状の治療に有効であることが証明されています。

世界的にペットの飼育数が増加し、ペットのライフスタイルや健康に対する支出が急増していることが、動物幹細胞療法市場の主要な促進要因となっています。加えて、慢性疾患や健康に関連する疾患の有病率が動物の間で上昇しており、幹細胞療法の需要を押し上げています。技術の進歩に伴い、幹細胞療法にAIを導入する動向が目立ってきています。AIは、精度を高め、治療中の合併症に対処するためのかつてないツールであることが証明されつつあります。このツールは、幹細胞コロニーの分類、細胞形態の同定、がん幹細胞における未記載の形態学的特徴の特徴づけ、薬剤効果の予測など、さまざまな手順のための信頼性の高い枠組みを設計するのに役立ちます。

しかし、動物幹細胞療法には多額の費用がかかるため、予算が限られているペットの飼い主はこうした治療を受けることができないです。さらに、幹細胞の有用性をめぐる倫理的な配慮が市場開拓の妨げとなっています。例えば、欧州医薬品庁（European Medicines Agency）は、動物用幹細胞療法に関する厳格な評価プロセスを導入しています。

セグメント別レビュー

動物幹細胞療法市場は、タイプ、種、エンドユーザー、地域に区分されます。タイプ別では、同種幹細胞療法と自家幹細胞療法に二分されます。種では、イヌ、ネコ、ウマに分けられます。エンドユーザー別では、動物病院と研究機関に分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

タイプ別では、同種異系が2023年に最も高い市場シェアを占めました。

エンドユーザー別では、犬セグメントが2023年の市場で高いシェアを獲得しました。

地域別では、北米が2023年に最も高い収益を上げました。

本レポートで可能なカスタマイズ（追加費用とスケジュールがあります。）

  • 顧客の関心に応じた企業プロファイルの追加

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 動物幹細胞療法：機会分析と産業予測、2024～2033年市場、タイプ別

  • 市場概要
  • 同種異系
  • 自己由来

第5章 動物幹細胞療法：機会分析と産業予測、2024～2033年市場、エンドユーザー別

  • 市場概要
  • 犬
  • 猫
  • 馬

第6章 動物幹細胞療法：機会分析と産業予測、2024～2033年市場、エンドユーザー別

  • 市場概要
  • 動物病院
  • 研究機関

第7章 動物幹細胞療法：機会分析と産業予測、2024～2033年市場、地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • カナダの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • メキシコの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
  • 欧州
    • 主要市場動向と機会
    • フランスの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • ドイツの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • イタリアの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • スペインの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • 英国の動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • その他の欧州の動物幹細胞療法：機会分析と産業予測、2024～2033年市場
  • アジア太平洋
    • 主要市場動向と機会
    • 中国の動物幹細胞療法：事業機会分析と産業予測、2024～2033年市場
    • 日本の動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • インドの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • 韓国の動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • オーストラリアの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • その他のアジア太平洋の動物幹細胞療法：機会分析と産業予測、2024～2033年市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • 南アフリカの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • サウジアラビアの動物幹細胞療法：機会分析と産業予測、2024～2033年市場
    • その他のラテンアメリカ・中東・アフリカ地域の動物幹細胞療法：機会分析と産業予測、2024～2033年市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第9章 企業プロファイル

  • Aratana Therapeutics, Inc.
  • VetStem, Inc.
  • Regeneus Ltd.
  • Magellan Stem Cells
  • PrimeGen Biotech, LLC
  • Vetbiologics
  • Boehringer Ingelheim
  • Cell Therapy Sciences
  • VETherapy Corporation
  • MediVet Biologics LLC
目次
Product Code: A324363

Animal Stem Cell Therapy Market

The animal stem cell therapy market was valued at $256.0 million in 2023 and is projected to reach $440.0 million by 2033, growing at a CAGR of 5.6% from 2024 to 2033.

Animal stem cell therapy is a procedure which involves the usage of stem cells to treat injuries or cure diseases in animals. Stem cells are the undifferentiated cells inside a living body which possess the capacity to give rise to new cells with different functionalities. This ability of stem cells makes them essential for the repair of damaged tissues and organs. To perform the therapy, the stem cells are harvested from diverse body parts, including bone marrow, umbilical cord blood, or fat tissue. The therapy has proven to be beneficial in the treatment of different conditions such as osteoarthritis, neurological disorders, tendon & ligament injuries, and various autoimmune diseases.

Increase in the ownership of pets globally, along with surge in expenditure on their lifestyle and health is a key driver of the animal stem cell therapy market. In addition, prevalence of chronic diseases and health-related disorders is rising among animals, thereby boosting the demand for stem cell therapy. With progressing technology, the trend of integrating AI in stem cell therapy is gaining prominence. AI is proving to be an unprecedented tool for achieving precision and addressing complications during the treatment. The tool helps to design a reliable framework for different procedures, including classification of stem cells colony, identification of cellular morphology, characterization of undescribed morphological traits in cancer stem cells, and prediction of drug effects.

However, the costs of animal stem cell therapies are significantly high, restricting the pet owners with limited budgets from affording such treatments. In addition, the market development is hampered by the ethical considerations surrounding the utility of stem cells, as compliance with such regulations is an intricate and lengthy procedure. For instance, the European Medicines Agency has implemented a rigorous evaluation process pertaining to stem cell therapies for veterinary use.

Segment Review

The animal stem cell therapy market is segmented into type, species, end user, and region. On the basis of type, the market is bifurcated into allogenic and autologous. As per species, it is divided into dog, cat, and horse. Depending on end user, it is classified into veterinary hospitals and research organizations. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the allogenic segment accounted for the highest market share in 2023.

As per species, the dog segment acquired high stakes in the market in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global animal stem cell therapy market include Aratana Therapeutics, Inc., VetStem, Inc., Regeneus Ltd., Magellan Stem Cells, PrimeGen Biotech, LLC, Vetbiologics, Boehringer Ingelheim, Cell Therapy Sciences, VETherapy Corporation, and MediVet Biologics LLC. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest

Key Market Segments

By Type

  • Allogenic
  • Autologous

By Species

  • Dog
  • Cat
  • Horse

By End User

  • Veterinary Hospitals
  • Research Organizations

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Aratana Therapeutics, Inc.
    • VetStem, Inc.
    • Regeneus Ltd.
    • Magellan Stem Cells
    • PrimeGen Biotech, LLC
    • Vetbiologics
    • Boehringer Ingelheim
    • Cell Therapy Sciences
    • VETherapy Corporation
    • MediVet Biologics LLC

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ANIMAL STEM CELL THERAPY BY TYPE, BY SPECIES (DOG, CAT, HORSE) BY END USER (VETERINARY HOSPITALS, RESEARCH ORGANIZATIONS) : OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST, 2024-2033 MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Allogenic
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Autologous
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: ANIMAL STEM CELL THERAPY BY TYPE, BY SPECIES (DOG, CAT, HORSE) BY END USER (VETERINARY HOSPITALS, RESEARCH ORGANIZATIONS) : OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST, 2024-2033 MARKET, BY SPECIES

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Species
  • 5.2. Dog
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Cat
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Horse
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: ANIMAL STEM CELL THERAPY BY TYPE, BY SPECIES (DOG, CAT, HORSE) BY END USER (VETERINARY HOSPITALS, RESEARCH ORGANIZATIONS) : OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST, 2024-2033 MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Veterinary Hospitals
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Research Organizations
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country

CHAPTER 7: ANIMAL STEM CELL THERAPY BY TYPE, BY SPECIES (DOG, CAT, HORSE) BY END USER (VETERINARY HOSPITALS, RESEARCH ORGANIZATIONS) : OPPORTUNITY ANALYSIS AND INDUSTRY FORECAST, 2024-2033 MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Species
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Species
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Species
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Species
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Species
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Species
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. Germany Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Species
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. Italy Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Species
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Spain Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Species
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. UK Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Species
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Species
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Species
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Species
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. Japan Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Species
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Species
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. South Korea Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Species
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. Australia Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Species
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Species
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Species
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Species
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. South Africa Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Species
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. Saudi Arabia Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Species
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Animal Stem Cell Therapy by Type, by Species (Dog, Cat, Horse) by End User (Veterinary Hospitals, Research Organizations) : Opportunity Analysis and Industry Forecast, 2024-2033 Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Species
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Aratana Therapeutics, Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. VetStem, Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Regeneus Ltd.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Magellan Stem Cells
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. PrimeGen Biotech, LLC
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Vetbiologics
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Boehringer Ingelheim
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Cell Therapy Sciences
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. VETherapy Corporation
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. MediVet Biologics LLC
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments